Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
$3.81
+1.5%
$2.66
$1.89
$4.09
$1.13B0.623.42 million shs1.95 million shs
ChromaDex Co. stock logo
CDXC
ChromaDex
$6.16
$2.41
$9.18
$611.50M2.21816,251 shs554,788 shs
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
$11.54
+12.0%
$9.42
$2.20
$12.78
$317.72M-0.59191,872 shs29,062 shs
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
$2.09
+1.7%
$2.14
$1.54
$3.97
$711.15M1.332.96 million shs3.37 million shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
0.00%+5.40%+60.55%+82.06%+40.41%
ChromaDex Co. stock logo
CDXC
ChromaDex
0.00%0.00%0.00%0.00%+209.65%
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
0.00%+25.63%+34.96%+77.52%+203.66%
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
0.00%+7.36%-16.10%+25.60%-28.72%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
2.4724 of 5 stars
3.41.00.00.03.23.30.0
ChromaDex Co. stock logo
CDXC
ChromaDex
3.2043 of 5 stars
3.50.00.04.00.00.01.9
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
3.7508 of 5 stars
4.43.00.00.02.62.50.6
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
3.4476 of 5 stars
4.60.00.00.02.45.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
2.75
Moderate Buy$8.33119.01% Upside
ChromaDex Co. stock logo
CDXC
ChromaDex
3.00
Buy$9.03∞ Upside
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
2.80
Moderate Buy$14.7527.83% Upside
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
3.20
Buy$7.17243.73% Upside

Current Analyst Ratings Breakdown

Latest DBVT, CDXC, NUVB, and ABCL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/26/2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/26/2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$21.00
6/25/2025
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$6.00
6/17/2025
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeOutperform ➝ Moderate Buy$10.00 ➝ $6.00
6/11/2025
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$5.00
6/2/2025
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$6.00
5/29/2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSell$7.25
5/27/2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
5/27/2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$15.00 ➝ $21.00
5/16/2025
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$28.00 ➝ $10.00
5/15/2025
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$5.00 ➝ $5.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
$28.83M39.39N/AN/A$3.58 per share1.06
ChromaDex Co. stock logo
CDXC
ChromaDex
$99.60M0.00N/AN/A$0.38 per share0.00
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
N/AN/AN/AN/A$1.42 per shareN/A
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
$7.87M90.15N/AN/A$1.37 per share1.52
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-$162.86M-$0.56N/AN/AN/A-737.56%-15.98%-12.38%8/5/2025 (Estimated)
ChromaDex Co. stock logo
CDXC
ChromaDex
-$4.94M$0.10787.290.00N/A1.62%4.85%2.70%N/A
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
-$113.92M-$4.92N/AN/AN/A-3,249.99%-278.24%-140.54%7/29/2025 (Estimated)
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
-$567.94M-$2.35N/AN/AN/A-5,534.21%-44.14%-32.97%8/4/2025 (Estimated)

Latest DBVT, CDXC, NUVB, and ABCL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/29/2025Q2 2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
-$0.28N/AN/AN/A$0.64 millionN/A
5/8/2025Q1 2025
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-$0.17-$0.15+$0.02-$0.15$7.12 million$4.24 million
5/7/2025Q1 2025
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
-$0.16-$0.16N/A-$0.16$0.42 million$3.08 million
4/11/2025Q4 2024
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
N/A-$1.10N/A-$1.10N/A$0.51 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
N/AN/AN/AN/AN/A
ChromaDex Co. stock logo
CDXC
ChromaDex
N/AN/AN/AN/AN/A
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
N/AN/AN/AN/AN/A
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
N/A
10.15
10.15
ChromaDex Co. stock logo
CDXC
ChromaDex
N/A
2.95
2.35
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
N/A
0.72
0.72
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
N/A
9.01
9.01

Institutional Ownership

CompanyInstitutional Ownership
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
61.42%
ChromaDex Co. stock logo
CDXC
ChromaDex
15.41%
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
71.74%
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
61.67%

Insider Ownership

CompanyInsider Ownership
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
28.90%
ChromaDex Co. stock logo
CDXC
ChromaDex
9.64%
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
1.44%
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
29.93%
CompanyEmployeesShares OutstandingFree FloatOptionable
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
500298.42 million212.18 millionOptionable
ChromaDex Co. stock logo
CDXC
ChromaDex
12077.75 million69.02 millionOptionable
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
8027.39 million27.00 millionOptionable
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
60340.26 million238.42 millionOptionable

Recent News About These Companies

Nuvation Bio (NYSE:NUVB) Shares Gap Up - Here's Why
Founder of Nuvation Bio David Hung Buys More Stock

New MarketBeat Followers Over Time

Media Sentiment Over Time

AbCellera Biologics stock logo

AbCellera Biologics NASDAQ:ABCL

$3.80 +0.06 (+1.47%)
Closing price 07/3/2025 03:56 PM Eastern
Extended Trading
$3.78 -0.02 (-0.53%)
As of 07/3/2025 04:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

ChromaDex stock logo

ChromaDex NASDAQ:CDXC

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.

DBV Technologies stock logo

DBV Technologies NASDAQ:DBVT

$11.54 +1.24 (+12.03%)
Closing price 07/3/2025 01:03 PM Eastern
Extended Trading
$11.59 +0.05 (+0.43%)
As of 07/3/2025 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Nuvation Bio stock logo

Nuvation Bio NYSE:NUVB

$2.08 +0.04 (+1.71%)
Closing price 07/3/2025 03:58 PM Eastern
Extended Trading
$2.07 -0.02 (-0.72%)
As of 07/3/2025 04:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.